The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National ...

The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...

Luton, Bedfordshire, United Kingdom, June 20, 2025 (GLOBE NEWSWIRE) -- The global drug development testing services market is entering a phase of robust expansion, driven by a surge in clinical trial ...

EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumor-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for ...

The program will bring together experts from across the FDA for a team-based review, rather than having an application move ...

Leaders of the FDA have published a list of new priorities for the agency. They want to deliver rapidly-approved cures and ...